| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MSH2, IHC with Interpretation
Test Code70197X
CPT Codes
88342
Preferred Specimen
Formalin-fixed paraffin embedded tissue in an IHC specimen transport kit
Other Acceptable Specimens
4-micron unstained slides • Fixed tissue • Tissue in neutral buffered formalin
Instructions
Pathology report is required
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Indefinite
Refrigerated: Indefinite
Frozen: Unacceptable
Refrigerated: Indefinite
Frozen: Unacceptable
Methodology
Immunohistochemical Stain
Setup Schedule
A.M.
Clinical Significance
Human mismatch repair protein 2 (MSH2) is involved in the initial recognition of mismatched nucleotides during the post replication mismatch repair process. Therefore, the loss of MSH2 function leads to the accumulation of replication errors, which in turn may be responsible for the multiple mutations required for mulistage carcinogenesis. Mutations in mismatch repair genes have been linked to hereditary nonpolyposis colon cancer and to sporadic cancers that exhibit microsatellite instability.
MSH2 is reported to be expressed in the nuclei of cells from a variety of tissues including thyroid, heart, smooth muscle, and the germinal centers of lymphoid follicles. In ileum and colon, MSH2 expression has been reported in the crypts, the cells of which are undergoing rapid renewal. They are responsible for the continuous of different cells which migrate over 2 to 4 days before being sloughed into the lumen. MSH2 is deicient in a high proportion of patients with microsatellite instability (MSI-H). This finding is associated with the autosomal dominant condition known as Hereditary Non-Polyposis Colon Cancer (HNPCC). The anti-MSH2 antibody is useful in screening patients and families for this condition. Colon cancers that are microsatellite unstable have a better prognosis than their microsatellite stable counterparts.
MSH2 is reported to be expressed in the nuclei of cells from a variety of tissues including thyroid, heart, smooth muscle, and the germinal centers of lymphoid follicles. In ileum and colon, MSH2 expression has been reported in the crypts, the cells of which are undergoing rapid renewal. They are responsible for the continuous of different cells which migrate over 2 to 4 days before being sloughed into the lumen. MSH2 is deicient in a high proportion of patients with microsatellite instability (MSI-H). This finding is associated with the autosomal dominant condition known as Hereditary Non-Polyposis Colon Cancer (HNPCC). The anti-MSH2 antibody is useful in screening patients and families for this condition. Colon cancers that are microsatellite unstable have a better prognosis than their microsatellite stable counterparts.
